 Home > Medical News > Latest Medical News > Teva again initiates patent lawsuit against Eli Lilly over migraine drug Emgality

Teva again initiates patent lawsuit against Eli Lilly over migraine drug Emgality

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

new drugs market

9 lead

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationFan Dongdong

The CGRP patent dispute between Ajovy manufacturer Teva and Emgality developer Eli Lilly is heating up again
.

On Tuesday, after the US Patent and Trademark Office obtained two new Ajovy patents, Teva filed a new lawsuit against Eli Lilly in the Federal Court of Massachusetts in the United States
.

The Israeli drugmaker said that Eli Lilly’s migraine prevention drug Emgality infringed two of Ajovy’s newly obtained patents
.

The company is seeking to prevent Eli Lilly from manufacturing and selling its CGRP inhibitor drug Emgality in the United States and is seeking compensation

Teva and Eli Lilly followed Amgen into the CGRP migraine market in 2018
.

After Emgality was approved, Teva sued Eli Lilly for alleged infringement of 9 Ajovy patents

Eli Lilly challenged the patents held by these Teva Ajovy in the US Patent and Trademark Office, with mixed results
.

The agency announced the invalidation of 6 patents held by Ajovy in early 2020, but maintained the remaining 3 patents

As Teva CEO Kåre Schultz makes a major business transformation, the company has identified Ajovy as a key growth driver
.

The company hopes that its innovative drugs can save the company from the loss of sales caused by the sluggish US generic drug market and the loss of exclusive patents for the once best-selling multiple sclerosis drug Copaxone

Ajovy is a monoclonal antibody drug that targets the calcitonin-related gene peptide (CGRP) ligand and blocks its binding to the receptor
.

CGRP is a neuropeptide that has been shown to be released during migraine attacks and is considered to be the cause of migraine attacks

However, so far, Ajovy's performance is the weakest of the three anti-CGRP drugs
.

According to statistics from the Royal Bank of Canada Capital Markets on IQVIA data last week, Novartis and Amgen's Aimovig lead their peers with a market share of more than 40%

Schultz stated on a recent conference call that the company's goal is to eventually occupy one-third of the CGRP market in the next few years
.

Competition in the migraine market will intensify in 2021

Reference source: Teva, after locking up new Ajovy patents, sues Eli Lilly again in heated migraine drug fight

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.